-
Chinese Society of Clinical Oncology (CSCO) Elects New Council Members
Election of New Council Members Professor Xu Ruihua, the President of CSCO and from Sun Yat-sen University Cancer Center, delivered a comprehensive and in-depth report on the work of the…
-
Dr. Peiqi Zhao: New Drug Developments and Optimized Management – Upgrading the Comprehensive Treatment Strategy for Follicular Lymphoma
From September 6 to 8, 2024, the 5th Tianjin International Lymphoma Conference was grandly held, attracting global experts to foster academic exchange and cooperation. During the conference, Hematology Frontier invited Dr. Peiqi Zhao from Tianjin Medical University Cancer Institute and Hospital to discuss the latest advances in follicular lymphoma treatment and the evolving concept of…
-
Dr. Lin Shen’s Team Confirms Promising Efficacy of Immunotherapy Combined with Chemotherapy as Neoadjuvant Treatment for Locally Advanced Esophageal
In April 2024, the 115th Annual Meeting of the American Association for Cancer Research (AACR) was held in San Diego, USA. As a global bellwether for new cancer drug development, the AACR meeting showcased numerous cutting-edge research findings in the field of oncology. One such study, conducted by Dr. Lin Shen’s team from Peking Cancer…
-
Dr. Xiubao Ren: Exploring Tumor Immunotherapy from a “Reverse” Perspective – The Practice of Reverse Immune Editing Therapy
The 5th Tianjin International Lymphoma Conference was successfully held from September 6 to 8, 2024. The conference featured 12 specialized sessions, including immunotherapy, basic translational research, and new drug development, providing a platform for international academic exchange and collaboration. During the event, Hematology Frontier invited Dr. Xiubao Ren from Tianjin Medical University Cancer Institute and…
-
Hepatology丨MELD-Na Score Predicts Long-Term Clinical Outcomes After TIPS Surgery
Traditionally, TIPS has been regarded as a bridge to liver transplantation (LT). However, recent findings suggest that some patients achieve long-term transplant-free survival (TFS) with TIPS alone. Therefore, clinicians should…
-
Dr. Shuquan Cheng: Common Factors Hindering Functional Cure in Chronic Hepatitis B
The reduction of hepatitis B surface antigen (HBsAg) levels in treated chronic hepatitis B (CHB) patients is closely linked to decreased risks of cirrhosis and even liver cancer. However, spontaneous HBsAg clearance occurs in less than 1% of patients per year. As CHB prevention and treatment guidelines continue to evolve both domestically and internationally, more…
-
Chinese Innovative Drug Takes the International Stage, Offering New Treatment Options for Intermediate and High-Risk Myelofibrosis Patients
From September 13 to 17, 2024, the European Society for Medical Oncology (ESMO) Annual Meeting is being held in Barcelona, Spain. As one of the top international oncology conferences, the event gathers experts and scholars from around the world to share cutting-edge research and discuss future developments. In the Mini Oral Session on Hematologic Malignancies,…
-
BV Combined with R2 Regimen Significantly Improves Overall Survival in Patients with Relapsed/Refractory DLBCL
The treatment of relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) has always been a significant challenge and a hot topic in the field of hematologic malignancies. For these patients, treatment options are extremely limited after multiple lines of therapy. Their salvage therapy has a low remission rate and short survival time. Currently, there is an…
Connecting Medical Expertise through Media